BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21932589)

  • 1. Evaluation of bone density in girls with precocious and early puberty during treatment with GnRH agonist.
    Assa A; Weiss M; Aharoni D; Mor A; Rachmiel M; Bistritzer T
    J Pediatr Endocrinol Metab; 2011; 24(7-8):505-10. PubMed ID: 21932589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
    Boot AM; De Muinck Keizer-Schrama S; Pols HA; Krenning EP; Drop SL
    J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy.
    van der Sluis IM; Boot AM; Krenning EP; Drop SL; de Muinck Keizer-Schrama SM
    J Clin Endocrinol Metab; 2002 Feb; 87(2):506-12. PubMed ID: 11836277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.
    Kapteijns-van Kordelaar S; Noordam K; Otten B; van den Bergh J
    Eur J Pediatr; 2003 Nov; 162(11):776-80. PubMed ID: 13680381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in bone mineral density and body composition in children with central precocious puberty and early puberty before and after one year of treatment with GnRH agonist.
    Ko JH; Lee HS; Lim JS; Kim SM; Hwang JS
    Horm Res Paediatr; 2011; 75(3):174-9. PubMed ID: 20881364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation.
    Antoniazzi F; Zamboni G; Bertoldo F; Lauriola S; Mengarda F; Pietrobelli A; Tatò L
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1096-101. PubMed ID: 12629090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment.
    Antoniazzi F; Bertoldo F; Lauriola S; Sirpresi S; Gasperi E; Zamboni G; Tatò L
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1992-6. PubMed ID: 10372699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty.
    Saggese G; Bertelloni S; Baroncelli GI; Battini R; Franchi G
    Eur J Pediatr; 1993 Sep; 152(9):717-20. PubMed ID: 8223799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment.
    Borderie D; Cherruau B; Dougados M; Ekindjian OG; Roux C
    Calcif Tissue Int; 1998 Jan; 62(1):21-5. PubMed ID: 9405728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
    Pasquino AM; Pucarelli I; Accardo F; Demiraj V; Segni M; Di Nardo R
    J Clin Endocrinol Metab; 2008 Jan; 93(1):190-5. PubMed ID: 17940112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females.
    Bertelloni S; Baroncelli GI; Sorrentino MC; Perri G; Saggese G
    Eur J Pediatr; 1998 May; 157(5):363-7. PubMed ID: 9625331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density and body composition in Thai Precocious Puberty girls treated with GnRH agonist.
    Wacharasindhu S; Petwijit T; Aroonparkmongkol S; Srivuthana S; Kingpetch K
    J Med Assoc Thai; 2006 Aug; 89(8):1194-8. PubMed ID: 17048429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density and body composition in girls with idiopathic central precocious puberty before and after treatment with a gonadotropin-releasing hormone agonist.
    Alessandri SB; Pereira Fde A; Villela RA; Antonini SR; Elias PC; Martinelli CE; Castro Md; Moreira AC; Paula FJ
    Clinics (Sao Paulo); 2012; 67(6):591-6. PubMed ID: 22760897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty.
    Park HK; Lee HS; Ko JH; Hwang IT; Lim JS; Hwang JS
    Clin Endocrinol (Oxf); 2012 Nov; 77(5):743-8. PubMed ID: 22530679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone mineral content in girls with precocious puberty treated with gonadotropin-releasing hormone analog.
    Verrotti A; Chiarelli F; Montanaro AF; Morgese G
    Gynecol Endocrinol; 1995 Dec; 9(4):277-81. PubMed ID: 8629454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for the effect of gonadotrophin releasing hormone analogue therapy on the height of girls with idiopathic central precocious puberty.
    Brauner R; Malandry F; Rappaport R
    Eur J Pediatr; 1992 Oct; 151(10):728-30. PubMed ID: 1425790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.
    Zamberlan N; Castello R; Gatti D; Rossini M; Braga V; Fracassi E; Adami S
    Osteoporos Int; 1997; 7(2):133-7. PubMed ID: 9166393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of changes in bone turnover and bone density associated with regaining weight in women with anorexia nervosa.
    Bolton JG; Patel S; Lacey JH; White S
    Osteoporos Int; 2005 Dec; 16(12):1955-62. PubMed ID: 16027954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.